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Abstract
Background Topical preparations, high in phosphate, may
cause calcification when used on a damaged corneal
surface. The knowledge of the phosphate concentration in
medications helps to prevent corneal calcifications. Our
study gives an overview of the amount of phosphate
contained in ophthalmic corticoid preparations.
Methods Samples of 38 commercially available corticoid
preparations were tested. The quantification of phosphate
was performed using the molybdate method on a Modular P
autoanalyzer.
Results 18 of 38 preparations (47%) had a phosphate
concentration above physiological levels (>1.45 mmol/l).
It varied greatly, and ranged from less than 0.1 mmol/l
(18 preparations) to 62.6 mmol/l. The corticoids that
were tested included betamethasone sodium phosphate
(18.3–35.5 mmol/l), dexamethasone (0.1–17.6 mmol/l),
dexamethasone sodium phosphate (<0.1–62.6 mmol/l),
fluorometholone (<0.1–22.5 mmol/l), and prednisolone
acetate (<0.1–0.5 mmol/l).
Conclusions The phosphate concentration in corticoid-
phosphate formulations varies greatly, and is mainly
determined by the chosen buffer. The prednisolone acetate
preparations showed physiological phosphate concentra-
tions. For a treatment on a damaged corneal surface,
preparations with physiological phosphate concentrations
should be used.
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Introduction
Eye-drop preparations, high in phosphate, may cause severe
corneal calcification when used on a damaged ocular
surface [1–4]. Daly et al. reported rapid corneal calcification
in chemically injured eyes after irrigation with phosphate-
buffered saline [2]. Similar irreversible deposits were
described after ocular surface disease and frequent use of
phosphate-buffered hyaluronic acid artificial tears [3], and
after amniotic membrane transplantation with phosphate-rich
lubrication [4].
Different corticoid compounds are presently used for the
topical treatment of chemical burns, postoperative tissue
injury, ocular surface disease and inflammatory conditions
[5]. Affected eyes may develop corneal epithelial defects,
and thus become susceptible to corneal calcification when
exposed to phosphate-rich preparations.
There is only a small amount of information on the
phosphate content of topical preparations [6] since buffers are
regarded as additives. In preparations containing corticoid-
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Table 1 Phosphate concentration in commercially available preparations that contain corticoids (German and Swiss market)
Pharmacological agents Type of Corticoid Phosphate 
PO4--- 
mmol/l 
Market 
Germany (GER) 
Switzerland (CH) 
Steroids 
Dexafree DU 0.1% (Théa Pharma) Dexamethasone sodium phosphate 29.4
DexaEDO (Mann) Dexamethasone sodium phosphate 33.1
Dexagel (Mann) Dexamethasone sodium phosphate <0.1
Dexapos (Ursapharm) Dexamethasone sodium phosphate <0.1
Dexa-sine SE (Alcon) Dexamethasone sodium phosphate 48.1
Efflumidex (Pharm-Allergan) Fluorometholone 21.1
Fluoro-Ophthal (Winzer) Fluorometholone 12.7
Fluoropos (Ursapharm) Fluorometholone 11.7
FML Liquifilm (Allergan) Fluorometholone 22.5
Inflanefran Forte (Pharm-Allergan) Prednisolone acetate <0.1
Isopto-Dex (Alcon) Dexamethasone 11.4
Maxidex (Alcon) Dexamethasone 17.6 CH 
CH 
CH 
GER
GER
GER
GER
GER
GER
GER
GER
GER
Predforte (Allergan) Prednisolone acetate 0.5
Predni-POS (Ursapharm) Prednisolone acetate <0.1
Spersadex mono 0.1% (OmniVision) Dexamethasone sodium phosphate <0.1
Totocortin (Winzer) Dexamethasone sodium phosphate 34.2
Ultracortenol (Novartis Pharma) Prednisolone acetate <0.1 GER, CH 
GER, CH 
Vexol (Alcon) Rimexolone <0.1 GER, CH 
Steroid combined with antibiotics 
Betagentam Augentropfen (Winzer) Betamethasone sodium phosphate 18.3 GER 
GER 
GER 
Cibaflam Augentropfensuspension (Novartis Pharma) Fluorometholone <0.1 GER 
Dexa-Gentamicin (Ursapharm) Dexamethasone sodium phosphate 52.6 GER 
Dexamytrex -Augentropfen (Mann) Dexamethasone sodium phosphate 62.6 GER 
Dexa-Polyspectran (Alcon) Dexamethasone sodium phosphate 2.8 GER 
Dispadex comp. (OmniVision) Dexamethasone sodium phosphate <0.1 GER 
GER 
GER 
GER 
FML-Neo Liquifilm ( Allergan) Fluorometholone 22.5 CH 
CH 
CH 
CH 
Frakidex (Novartis Pharma) Dexamethasone sodium phosphate <0.1
Infectoflam (Novartis Pharma) Fluorometholone <0.1
Inflanegent Liquifilm (Pharm-Allergan) Prednisolone acetate <0.1
Isopto-Max (Alcon) Dexamethasone <0.1
Maxitrol (Alcon) Dexamethasone <0.1 GER, CH 
GER, CH 
Mycinopred (Allergan) Prednisolone acetate 0.2 CH 
CH 
CH 
Neo-Hydro Augentropfen (Streuli Pharma) Hydrocortisone acetate <0.1
Ophtasone (Bausch & Lomb Switzerland) Betamethasone sodium phosphate 35.5
Terracortril N Betamethason + Gentamicin  (Mann) Betamethasone sodium phosphate 18.4
Tobradex (Alcon) Dexamethasone <0.1
Steroid with chloamphenicol 
Aquapred-N (Winzer) Prednisolone sodium phosphate 1.5 GER 
Steroid and vasoconstrictor 
Efemoline (Novartis) Fluorometholone <0.1 GER, CH 
Steroid and disinfection 
Dexa Biciron (Alcon) Dexamethasone isonicotinate <0.1 GER 
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phosphates, small amounts (<0.1 mmol/l) of free phosphate
anions may be due to ester hydrolysis. Phosphorylated
corticoids are popular with manufacturers, since they allow
preparation of a clear solution [5].
Our study investigates the amount of phosphate contained
in ophthalmic corticoid preparations. This information
should help to prevent sight-threatening corneal calcification.
Materials and methods
All the ophthalmic drop preparations that contain corticoids
and that are listed in the “Rote Liste 2007” (Rote Liste Service
GmbH, Frankfurt/Main, Editio Cantor Verlag, Aulendorf,
Germany) and the “Arzneimittelkompendium der Schweiz
2007” (Documed AG, Basel, Switzerland) were included in
this study. When the preparations were available in multidose
and unit dose containers, the samples were taken from the
preservative-free formulation. For technical reasons, gel
preparations were not included. The quantification of the
phosphate was performed with the molybdate method on a
Modular P autoanalyzer (Roche Diagnostics, Basel, Switzer-
land) [7]. The precision of these measurements was
guaranteed by the inclusion of standardised phosphate
solutions as controls. The day-to-day coefficient of variation
was 1.7%. The results were compared to the physiological
concentrations published elsewhere [7, 8].
Results
The phosphate concentrations of the ocular therapeutics that
were studied are given in Table 1. The preparations are listed in
alphabetical order and in groups of active drugs. The steroid
compound of the therapeutic is shown in the second column.
Eighteen of 38 corticoid preparations (47%) had a phosphate
concentration above physiological levels (>1.45 mmol/l). The
concentration varied greatly and ranged from less than 0.1 to
62.6 mmol/l. Medications with betamethasone sodium phos-
phate showed phosphate concentrations from 18.3 to
35.5 mmol/l, dexamethasone from less than 0.1 to
17.6 mmol/l, dexamethasone sodium phosphate from <0.1
to 62.6mmol/l, fluorometholone from <0.1 to 22.5mmol/l, and
prednisolone acetate from <0.1 to 0.5 mmol/l.
Discussion
Ophthalmic preparations with corticoids may contain high
concentrations of free phosphate. Several medications with
phosphorylated corticoids were, however, very low in free
phosphate ion (Table 1). This indicates that in corticoid eye
drops, as in other ophthalmic preparations [9, 10], the total
amount of free phosphate ion is primarily determined by the
choice of the buffers, and that phosphate ester bounds resist
hydrolysis.
In ophthalmic preparations, the vehicle is an agent other
than the active drug or preservative. It is added to a
formulation to provide proper tonicity, buffering, and viscosity
to complement drug action [11]. Its buffering system may
consist of acetic, boric and hydrochloric acid, and of
potassium or sodium bicarbonate, borate, phosphate and
citrate [11]. Phosphates are presently widely used in
ophthalmic preparations due to their high buffering capacity
around pH 7.4.
Phosphate buffers, however, play a role in the process of
inadvertent corneal calcification [1–4, 12]. Calcification
occurs when calcium cations and phosphate anions interact
within the tissue to form insoluble crystals. In the cornea,
deposition typically occurs as hydroxylapatite Ca5(PO4)3OH
[2, 3]. Deposition can be observed as a spectrum of clinical
findings, ranging from subtle superficial changes to massive
calcification of the entire cornea with visual loss.
“Boundary conditions” for the onset of corneal calcifi-
cation, particularly a critical concentration of phosphate
anions, cannot be defined at present. In an animal model,
rapid corneal calcification developed after chemical injury,
combined with a large epithelial defect, an alkaline pH,
when the eyes were irrigated with Isogutt (Dr. Winzer
Pharma GmbH, Germany) [1]. In this formulation, a
phosphate concentration of 148 mol/l was measured [6].
The amount of phosphate ion delivered to the ocular
surface by ophthalmic corticoid formulations may appear
minor when compared to the treatment of chemical injuries
or epithelial defects with artificial tears [3, 9]. It has to be
borne in mind, however, that the ion product of calcium
cations and phosphate anions in aqueous humour, tears and
interstitial fluids is, even under physiological conditions,
close to their solubility product. A minor increase of one of
the components may therefore push this system towards
precipitation. Furthermore, corticoids are often used in
severely damaged eyes that are prone to the complication of
calcification. The high phosphate concentration of some
steroid preparations may therefore trigger the process of
crystallisation. We do recommend that steroid preparations
with physiological phosphate concentrations are used in
order to reduce the risk of corneal calcification, particularly
when frequent application is required.
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